产品名称 | NebuPeptide™ Trofinetide (Peptide Reference) 曲非奈肽 |
---|---|
目录号 | NBS-233783 |
别名 | NNZ-2566; Daybue; NNZ2566; NNZ 2566 |
外观 | see COA |
分子量 | 315.32 |
CAS | 853400-76-7 |
溶解度 | see COA |
存储条件 | Store at -20℃ |
保存时间 | see COA |
备注1 | |
备注2 |
目录号 | 规格 | 价格 | 库存状态 | |
NBS-233783-1mg | 1mg | 咨询 | 现货 | |
NBS-233783-5mg | 5mg | 咨询 | 现货 | |
NBS-233783-100mg | 100mg | 咨询 | 现货 | |
NBS-233783-1g | 1g | 咨询 | 现货 | |
NBS-233783-Bulk | Bulk | 咨询 | 咨询 |
Product Name:
NebuPeptide™ Trofinetide (Peptide Reference)
Catalog Number:
NBS-233783
Description:
NebuPeptide™ Trofinetide (Peptide Reference)(CAT#NBS-233783) is synthesized in accordance with the Trofinetide sequence and can be utilized for a variety of in vivo and in vitro studies, including quality control, bioactivity verification, immunization, drug development, structural analysis, etc. Nebula Biotechnology Co., Ltd. is capable of providing Etelcalcetide reference peptide ranging from milligrams to kilograms.
Peptide Name:
Trofinetide (曲非奈肽)
Background:
Trofinetide (NNZ-2566; NNZ2566; Daybue) is a novel and potent glypromate (or Gly-Pro-Glu) analog and neuroprotectant. It can improve functional recovery and attenuate apoptosis and inflammation in a rat model of penetrating ballistic-type brain injury. Trofinetide showed neuroprotective efficacy in models of traumatic brain injury. It significantly decreases injury-induced upregulation of inflammatory cytokines including TNF-α, IFN-γ, and IL-6. Trofinetide has the potential to be used for fragile X syndrome. In Mar 2023, it has been approved by FDA for the treatment of Rett syndrome.
Alias:
NNZ-2566; Daybue; NNZ2566; NNZ 2566
CAS Number:
853400-76-7
Formula:
C13H21N3O6
Molecular Weight:
315.32
Purity:
see COA
Solubility:
see COA
Storage & Shipment:
Store at -20℃; ship with blue ice.
For R&D use only!
To get more information, please contact us freely.